Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Non-Current Liabilities (2019 - 2021)

Historic Total Non-Current Liabilities for Pliant Therapeutics (PLRX) over the last 3 years, with Q4 2021 value amounting to $22.2 million.

  • Pliant Therapeutics' Total Non-Current Liabilities rose 9101.65% to $22.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was $22.2 million, marking a year-over-year increase of 9101.65%. This contributed to the annual value of $22.2 million for FY2021, which is 9101.65% up from last year.
  • As of Q4 2021, Pliant Therapeutics' Total Non-Current Liabilities stood at $22.2 million, which was up 9101.65% from $12.9 million recorded in Q3 2021.
  • In the past 5 years, Pliant Therapeutics' Total Non-Current Liabilities ranged from a high of $22.2 million in Q4 2021 and a low of $8.2 million during Q4 2019
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $11.3 million (2020), whereas its average is $12.4 million.
  • Data for Pliant Therapeutics' Total Non-Current Liabilities shows a peak YoY increase of 9101.65% (in 2021) and a maximum YoY decrease of 917.25% (in 2021) over the last 5 years.
  • Over the past 3 years, Pliant Therapeutics' Total Non-Current Liabilities (Quarter) stood at $8.2 million in 2019, then surged by 41.94% to $11.6 million in 2020, then skyrocketed by 91.02% to $22.2 million in 2021.
  • Its Total Non-Current Liabilities stands at $22.2 million for Q4 2021, versus $12.9 million for Q3 2021 and $10.9 million for Q2 2021.